Oligomerix Publishes Preclinical Data on Novel Small Molecule Therapeutic in Development for Alzheimer’s Disease and Rare Neurodegenerative Diseases

Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010

Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases

Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer’s Disease (CTAD) and Neuroscience 2022 Meetings

Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010

Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy

Oligomerix Announces Key Organizational Changes in Transition to Clinically Focused Company

Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development

Oligomerix Presents Data on Lead Program at Clinical Trials on Alzheimer’s Disease (CTAD) Conference and Society for Neuroscience Meeting

Oligomerix Presents Preclinical Data Showing Efficacy of Differentiated Approach Targeting Tau in Models of Alzheimer’s Disease and Related Tauopathies